Welcome to Part 2 of the 2022 Forum on Complement Case Discussion Series. PNH is an ultra-rare, and under-recognized complement-mediated disease. Despite its rarity this disease warrants our attention because…

Welcome to the Part 2 of the 2022 HPP Case Discussion. In October 2021- January 2022, insights on current perceptions and practice patterns were collected from specialists across Canada via a…

Welcome to the Part 1 of the 2022 Forum on Complement Case Discussion.

Introduction   The armamentarium of therapies available for our CLL patients has rapidly grown in recent years. As novel agents have become integrated into routine practice, navigating optimal use and...

Welcome to the Part 1 of the 2022 HPP Case Discussion. In October 2021- January 2022, insights on current perceptions and practice patterns were collected from specialists across Canada via…

This program provided a forum for Canadian clinicians and allied health care professionals to learn and connect with Canadian experts and peers. The goals of the meeting: To highlight key…

The CARE™ Prostate Cancer Faculty reviews important publications and data throughout the year. Clinically relevant trial updates from recent months are outlined within this report with additional context for how…

The SHU event was held June 24th 2022, leading Canadian hematologists contextualized recent international news and data in hematology framing the news from a Canadian perspective.

The CARE™ Rheumatology Perspectives report provides Canadian perspectives on relevant clinical trials and news in inflammatory arthritis.

Introduction Welcome to the third, and final, installment of the CARE™ nmCRPC Case Series! This series aims to provide guidance on navigating the evolving treatment landscape and some of the...